Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-821 as Adjunctive Therapy in Adults With Major Depressive Disorder
NCT07226661Phase 2Recruiting
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing SPN-821 2400 mg with Placebo (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 4 weeks. Started Jan 2026; status: recruiting.
02
Drugs
mefluleucine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07226661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226661.